Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma

Inclusion Criteria: * Measurable disease (\>= 1.5 cm) as assessed by 2 dimensional measurement by computed tomography (CT) * Previously untreated stage I or II non-bulky (defined as a mass measuring \< 10 cm in the longest dimension by CT) classical Hodgkin lymphoma * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2 * Life expectancy \>= 3 months * Documented negative serologic testing for human immunodeficiency virus (HIV), hepatitis B (unless serologically positive due to prior vaccination), and hepatitis C =\< 1 year prior to registration * White blood cell \>= 2,000 /mm\^3 without transfusion support \> 7 days prior to registration * Hemoglobin \>= 8.5 g/dL without transfusion support \> 7 days prior to registration * Absolute neutrophil count (ANC) \>= 1,000 cells/mm\^3 without transfusion support \> 7 days prior to registration * Platelet count \>= 75,000/mm\^3 without transfusion support \> 7 days prior to registration * Alanine and aspartate aminotransferase (ALT/AST) =\< 2.5 x upper limit of normal (ULN) obtained =\< 14 days prior to registration * Total serum bilirubin =\< 1.5 x ULN (if documented Gilberts syndrome =\< 3 x ULN) obtained =\< 14 days prior to registration * Serum creatinine =\< 1.5 x ULN or measured calculated creatinine clearance \>= 40 ml/min for subject with creatinine levels \> 1.5 x institutional ULN (per Cockcroft-Gault formula) obtained =\< 14 days prior to registration * Negative serum pregnancy test (minimum sensitivity …